ASH 2022 | Unmet needs in SR-aGvHD and TR-aGvHD
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, shares insights into the unmet needs of steroid- and treatment-refractory acute graft-versus-host disease (aGvHD). Dr Abedin highlights that whilst the durability and depth of response was shown to be superior with ruxolitinib compared to best available therapy (BAT) in the REACH2 trial (NCT0291326), an emerging population of patients requiring additional therapy after ruxolitinib highlights the need for novel agents to ensure adequate control of aGvHD. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Helsinn Healthcare: Research Funding; Pfizer: Research Funding; Actinium Pharmaceuticals: Research Funding; AltruBio Inc.: Research Funding; Stemline: Honoraria; Amgen: Honoraria; Incyte: Research Funding; AbbVie: Honoraria; Daichi Sankyo: Honoraria; Servier: Honoraria.
